← All trials
NCT05653037
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- Dec 16, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 64
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Ribo Life Science Co. Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.